PMV PHARMACEUTICALS INC (PMVP) Stock Price, Forecast & Analysis
NASDAQ:PMVP • US69353Y1038
PMVP Key Statistics, Chart & Performance
The current stock price of PMVP is 1.37 USD. In the past month the price increased by 12.3%.
PMVP Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PMVP. When comparing the yearly performance of all stocks, PMVP turns out to be only a medium performer in the overall market: it outperformed 44.56% of all stocks.
PMVP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PMVP. While PMVP has a great health rating, there are worries on its profitability.
PMVP Financial Highlights
Over the last trailing twelve months PMVP reported a non-GAAP Earnings per Share(EPS) of -1.6. The EPS decreased by -60% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.79% | ||
| ROE | -68.35% | ||
| Debt/Equity | 0 |
PMVP Forecast & Estimates
12 analysts have analysed PMVP and the average price target is 7.75 USD. This implies a price increase of 465.84% is expected in the next year compared to the current price of 1.37.
PMVP Ownership
PMVP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.47 | 401.054B | ||
| AMGN | AMGEN INC | 16.83 | 206.954B | ||
| GILD | GILEAD SCIENCES INC | 16.12 | 182.529B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.55 | 122.559B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 82.914B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.45 | 43.248B | ||
| INSM | INSMED INC | N/A | 31.694B | ||
| NTRA | NATERA INC | N/A | 29.474B | ||
| BIIB | BIOGEN INC | 12.36 | 27.992B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.09 | 23.041B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PMVP
Company Profile
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company is headquartered in Princeton, New Jersey and currently employs 63 full-time employees. The company went IPO on 2020-09-25. The firm is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. The company is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.
Company Info
PMV PHARMACEUTICALS INC
400 Alexander Park Drive, Suite 301
Princeton NEW JERSEY 08512 US
CEO: David H. Mack
Employees: 63
Phone: 13026365400
PMV PHARMACEUTICALS INC / PMVP FAQ
What does PMVP do?
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company is headquartered in Princeton, New Jersey and currently employs 63 full-time employees. The company went IPO on 2020-09-25. The firm is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. The company is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.
Can you provide the latest stock price for PMV PHARMACEUTICALS INC?
The current stock price of PMVP is 1.37 USD. The price increased by 22.32% in the last trading session.
Does PMV PHARMACEUTICALS INC pay dividends?
PMVP does not pay a dividend.
What is the ChartMill technical and fundamental rating of PMVP stock?
PMVP has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PMVP stock listed?
PMVP stock is listed on the Nasdaq exchange.
Can you provide the number of employees for PMV PHARMACEUTICALS INC?
PMV PHARMACEUTICALS INC (PMVP) currently has 63 employees.
What is PMV PHARMACEUTICALS INC worth?
PMV PHARMACEUTICALS INC (PMVP) has a market capitalization of 72.90M USD. This makes PMVP a Micro Cap stock.